Latest Report

2017 - Q3 Quarterly Report

Prometic reports third quarter 2017 highlights and financial results:
- US $80 million (CAD $100 million) line of credit secured from Structured Alpha LP
- Plasminogen BLA accepted by FDA, PDUFA date fixed at April 14, 2018
- Plasminogen granted rare pediatric disease designation by FDA and priority review status by Health Canada
- PBI-4050 granted Fast Track designation for IPF and green light to initiate the pivotal phase 2/3 clinical trials
- Conference call and live webcast at 11:00 am ET on Tuesday November 14


Annual Report

Annual Report 2016

Building a company to bring safer therapeutic products.

Download Link View all reports


Prometic Corporate Presentation January 2017

Experts in bioseparation, plasma derived and small molecule drugs.

Download Link View all presentations